Community-Acquired Infections – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 13 PAGES: 54

More Info
									Community-Acquired Infections – Pipeline Review, H1 2012




 Community-Acquired Infections – Pipeline Review, H1
                       2012
                                                                                          Reference Code: GMDHC1714IDB
                                                                                            Publication Date: January 2012




Community-Acquired Infections – Pipeline Review, H1 2012                                   GMDHC1714IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Community-Acquired Infections – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Community-Acquired Infections Overview .......................................................................................................................................... 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Community-Acquired Infections.......................................................................................... 7
Community-Acquired Infections Therapeutics under Development by Companies ............................................................................ 9
Late Stage Products ......................................................................................................................................................................... 11
    Comparative Analysis .................................................................................................................................................................. 11
Mid Clinical Stage Products.............................................................................................................................................................. 12
    Comparative Analysis .................................................................................................................................................................. 12
Community-Acquired Infections Therapeutics – Products under Development by Companies ........................................................ 13
Companies Involved in Community-Acquired Infections Therapeutics Development ....................................................................... 14
    Rib-X Pharmaceuticals, Inc. ........................................................................................................................................................ 14
    Warner Chilcott Limited ............................................................................................................................................................... 15
    Optimer Pharmaceuticals, Inc...................................................................................................................................................... 16
    Paratek Pharmaceuticals, Inc. ..................................................................................................................................................... 17
    Dongwha Pharm Co., Ltd. ........................................................................................................................................................... 18
    Enanta Pharmaceuticals, Inc. ...................................................................................................................................................... 19
    Tetraphase Pharmaceuticals Inc. ................................................................................................................................................ 20
Community-Acquired Infections – Therapeutics Assessment........................................................................................................... 21
    Assessment by Monotherapy Products ....................................................................................................................................... 21
    Assessment by Route of Administration ...................................................................................................................................... 22
    Assessment by Molecule Type .................................................................................................................................................... 24
Drug Profiles..................................................................................................................................................................................... 26
    Omadacycline - Drug Profile ........................................................................................................................................................ 26
         Product Description................................................................................................................................................................. 26
         Mechanism of Action ............................................................................................................................................................... 26
         R&D Progress ......................................................................................................................................................................... 26
    RX-3341 - Drug Profile ................................................................................................................................................................ 28
         Product Description................................................................................................................................................................. 28
         Mechanism of Action ............................................................................................................................................................... 28
         R&D Progress ......................................................................................................................................................................... 28
    RX-1741 - Drug Profile ................................................................................................................................................................ 31
         Product Description................................................................................................................................................................. 31
         Mechanism of Action ............................................................................................................................................................... 31
         R&D Progress ......................................................................................................................................................................... 31
    OP-1068 - Drug Profile ................................................................................................................................................................ 33
         Product Description................................................................................................................................................................. 33
         Mechanism of Action ............................................................................................................................................................... 33



Community-Acquired Infections – Pipeline Review, H1 2012                                                                                     GMDHC1714IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Community-Acquired Infections – Pipeline Review, H1 2012




         R&D Progress ......................................................................................................................................................................... 33
    DW-224 - Drug Profile ................................................................................................................................................................. 35
         Product Description................................................................................................................................................................. 35
         Mechanism of Action ............................................................................................................................................................... 35
         R&D Progress ......................................................................................................................................................................... 35
    EDP-420 - Drug Profile ................................................................................................................................................................ 37
         Product Description................................................................................................................................................................. 37
         Mechanism of Action ............................................................................................................................................................... 37
         R&D Progress ......................................................................................................................................................................... 37
    Nemonoxacin - Drug Profile......................................................................................................................................................... 38
         Product Description................................................................................................................................................................. 38
         Mechanism of Action ............................................................................................................................................................... 38
         R&D Progress ...............................................................................
								
To top